Thursday, May 25, 2017 9:28:28 AM
Recent GLYC News
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 11/04/2024 07:01:21 PM
- Shares of Biotech Company Up Over 100% Premarket Following Merger & Funding Announcement • AllPennyStocks.com • 10/29/2024 02:00:00 PM
- Biotech Up Over +100% Premarket Following Merger And Funding Announcement • AllPennyStocks.com • 10/29/2024 02:00:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 10/29/2024 12:09:57 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/29/2024 12:09:13 PM
- GlycoMimetics Enters Into Acquisition Agreement With Crescent Biopharma • Business Wire • 10/29/2024 11:00:00 AM
- GlycoMimetics Announces National Cancer Institute Phase 2/3 Study of Uproleselan Did Not Meet Primary Endpoint • Business Wire • 10/29/2024 10:30:00 AM
- Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 08/15/2024 09:01:27 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/08/2024 08:00:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/30/2024 07:55:22 PM
- Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 07/29/2024 11:24:49 PM
- GlycoMimetics Announces Strategic Review and Corporate Restructuring Plan • Business Wire • 07/25/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/13/2024 08:30:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 01:30:15 PM
- GlycoMimetics Announces Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) • Business Wire • 06/04/2024 11:00:00 AM
- GlycoMimetics to Host Key Opinion Leader Event to Review Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) on June 4, 2024 • Business Wire • 05/29/2024 08:01:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:31:01 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2024 08:01:01 PM
- GlycoMimetics Announces Results of Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) • Business Wire • 05/06/2024 10:00:00 AM
- GlycoMimetics to Report First Quarter 2024 Financial Results on May 9, 2024 • Business Wire • 04/25/2024 11:00:00 AM
- GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2023 • Business Wire • 03/27/2024 11:00:00 AM
- GlycoMimetics to Report Fourth Quarter and 2023 Full Year Financial Results on March 27, 2024 • Business Wire • 03/13/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/01/2024 02:16:05 PM
- GlycoMimetics to Participate in Upcoming Cowen 44th Annual Health Care Conference • Business Wire • 02/26/2024 12:00:00 PM
FEATURED North Bay Resources Announces Assays up to 9.5% Copper at Murex Copper Project, British Columbia • Nov 4, 2024 9:00 AM
Rainmaker Worldwide Inc. Announces Strategic Partnership Between Miranda Water Technologies and Fleming College • RAKR • Nov 4, 2024 12:03 PM
Rainmaker Worldwide Inc. to Assume Direct, Non-Dealer Sales of Miranda Water Technologies in U.S. and Mexico in First Quarter of 2025 • RAKR • Nov 4, 2024 8:31 AM
CBD Life Sciences Inc. (CBDL) Launches High-Demand Mushroom Gummy Line for Targeted Wellness Needs, Tapping into a Booming $20 Billion Market • CBDL • Oct 31, 2024 8:00 AM
Nerds On Site Announces Q1 Growth and New Initiatives for the Remainder of 2024 • NOSUF • Oct 31, 2024 7:01 AM
Innovation Beverage Group Receives Largest Shipment of its Top-Selling Bitters to Date in the U.S.-Ready to Meet Growing Demand from Expanding Distribution Network • IBG • Oct 30, 2024 12:22 PM